# SMAD4

## Overview
SMAD4 is a gene that encodes the SMAD family member 4 protein, a pivotal intracellular mediator in the transforming growth factor-beta (TGF-β) signaling pathway. This protein is categorized as a signal transducer and transcriptional modulator, playing a crucial role in regulating cellular processes such as proliferation, differentiation, and apoptosis. The SMAD4 protein functions by forming heteromeric complexes with receptor-regulated SMADs (R-SMADs), such as SMAD2 and SMAD3, which then translocate to the nucleus to influence gene expression (Ten2002Regulation; Pierreux2000Transforming). Mutations in the SMAD4 gene are implicated in various hereditary conditions and cancers, including Juvenile Polyposis Syndrome and pancreatic ductal adenocarcinoma, highlighting its significance as a tumor suppressor (Howe1998Mutations; Bardeesy2006Smad4). The disruption of SMAD4 function can lead to aberrant TGF-β signaling, contributing to tumorigenesis and disease progression (Zhao2018The).

## Structure
The SMAD4 protein is composed of 552 amino acids and has a molecular weight of approximately 60 kDa (Zhao2018The). Its primary structure includes three major parts: the N-terminal MH1 domain, the C-terminal MH2 domain, and a linker region between them. The MH1 domain is responsible for DNA binding, while the MH2 domain is crucial for transcriptional activity and protein-protein interactions (Zhao2018The). The SMAD activation domain (SAD) is located at the C-terminal of the linker region and is essential for transcriptional activity (Zhao2018The).

The secondary structure of SMAD4 includes 4 α-helices, 12 β-sheets, and 3 loops, with a disorder region spanning approximately residues 1-270 and a structured region from residues 273-552 (Kumar2020Deciphering). The tertiary structure of SMAD4 has been modeled using homology and ab initio methods, revealing the impact of specific mutations on its conformation and function (Kumar2020Deciphering).

In terms of quaternary structure, SMAD4 forms heteromeric complexes with other SMAD proteins, such as SMAD2 and SMAD3, which are essential for its role in the TGF-β signaling pathway (Nolan2017Influential). These complexes are stabilized by electrostatic interactions, which are crucial for their function (Nolan2017Influential).

## Function
SMAD4 is a critical component of the transforming growth factor-beta (TGF-β) signaling pathway, which regulates cell proliferation, differentiation, and apoptosis in healthy human cells. It functions as a common mediator by forming complexes with receptor-regulated SMADs (R-SMADs) such as SMAD2 and SMAD3. These complexes translocate to the nucleus, where they regulate the expression of target genes involved in cell cycle control and other cellular processes (Ten2002Regulation; Pierreux2000Transforming).

SMAD4 is involved in the transcriptional activation of genes by binding to specific DNA sequences, often in conjunction with other transcription factors like Fast-1. It plays a role in the regulation of genes such as the plasminogen activator inhibitor 1 (PAI-1) promoter, which is responsive to TGF-β signaling (Pierreux2000Transforming; Yingling1997Tumor). SMAD4 also contributes to cell cycle arrest by upregulating cyclin-dependent kinase inhibitors, such as p15 INK4b and p21 CIP/WAF1, and downregulating c-Myc, which are crucial for inhibiting cell proliferation (Ten2002Regulation).

In terms of subcellular localization, SMAD4 shuttles between the cytoplasm and nucleus, a process regulated by nuclear import and export signals. This shuttling is essential for its role in mediating transcriptional responses to TGF-β (Ten2002Regulation; Pierreux2000Transforming).

## Clinical Significance
Mutations in the SMAD4 gene are associated with several hereditary conditions and cancers. SMAD4 mutations are linked to Juvenile Polyposis Syndrome (JPS), an autosomal dominant disorder characterized by the development of hamartomatous polyps in the gastrointestinal tract and an increased risk of gastrointestinal cancer (Howe1998Mutations). These mutations can lead to truncated SMAD4 proteins, disrupting normal function and contributing to tumor development (Howe1998Mutations). SMAD4 mutations are also implicated in Hereditary Hemorrhagic Telangiectasia (HHT), a condition marked by vascular dysplasia and arteriovenous malformations (Wain2014Appreciating).

In cancer, SMAD4 acts as a tumor suppressor, and its inactivation is frequently observed in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC). In PDAC, SMAD4 loss is often accompanied by KRAS mutations, accelerating cancer progression (Bardeesy2006Smad4). In CRC, SMAD4 mutations are associated with poor prognosis, higher tumor stages, and resistance to certain therapies (Yan2016Reduced; Fang2021Prognostic). SMAD4 alterations are also linked to poor outcomes in non-small cell lung cancer (NSCLC) and are associated with resistance to platinum-based chemotherapy (Wang2021SMAD4). These mutations disrupt the TGF-β signaling pathway, affecting cell proliferation, differentiation, and apoptosis, and contributing to cancer progression and metastasis (Zhao2018The).

## Interactions
SMAD4 is a central mediator in the TGF-β signaling pathway, forming both homomeric and heteromeric complexes with other SMAD proteins. It interacts with SMAD3 to form heteromeric complexes that are crucial for TGF-β-like responses. The C-terminal domain of SMAD4 is primarily responsible for these heteromeric interactions, while its N-terminal domain facilitates strong homomeric interactions (Wu1997Heteromeric). SMAD4 also interacts with SMAD2 and FAST-1 to form a ternary complex essential for DNA binding and transcriptional activation in response to TGF-β signals. The N domain of SMAD4 enhances DNA binding, while the C domain is crucial for transcriptional activation (Liu1997Dual).

In the context of mutant SMAD4, specifically the R361H mutation, small molecules like Ro-31-8220 can restore the impaired interaction between SMAD4 and SMAD3, reactivating TGF-β signaling in mutant cells. This restoration leads to the reactivation of transcriptional activity and the expression of TGF-β-responsive genes (Tang2021Hypomorph). SMAD4 also interacts with the orphan nuclear receptor HNF-4, modulating the transcription of genes with HNF-4 binding sites, such as the apoC-III gene (Chou2003Mechanism).


## References


[1. (Yan2016Reduced) Pu Yan, Dirk Klingbiel, Zenia Saridaki, Paola Ceppa, Monica Curto, Thomas Alexander McKee, Arnaud Roth, Sabine Tejpar, Mauro Delorenzi, Fredrik T. Bosman, and Roberto Fiocca. Reduced expression of smad4 is associated with poor survival in colon cancer. Clinical Cancer Research, 22(12):3037–3047, June 2016. URL: http://dx.doi.org/10.1158/1078-0432.ccr-15-0939, doi:10.1158/1078-0432.ccr-15-0939. This article has 53 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/1078-0432.ccr-15-0939)

[2. (Pierreux2000Transforming) Christophe E. Pierreux, Francisco J. Nicolás, and Caroline S. Hill. Transforming growth factor β-independent shuttling of smad4 between the cytoplasm and nucleus. Molecular and Cellular Biology, 20(23):9041–9054, December 2000. URL: http://dx.doi.org/10.1128/mcb.20.23.9041-9054.2000, doi:10.1128/mcb.20.23.9041-9054.2000. This article has 218 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.20.23.9041-9054.2000)

[3. (Liu1997Dual) Fang Liu, Celio Pouponnot, and Joan Massagué. Dual role of the smad4/dpc4 tumor suppressor in tgfβ-inducible transcriptional complexes. Genes &amp; Development, 11(23):3157–3167, December 1997. URL: http://dx.doi.org/10.1101/gad.11.23.3157, doi:10.1101/gad.11.23.3157. This article has 348 citations.](https://doi.org/10.1101/gad.11.23.3157)

[4. (Chou2003Mechanism) Wan-Chih Chou, Vassiliki Prokova, Keiko Shiraishi, Ulrich Valcourt, Aristidis Moustakas, Margarita Hadzopoulou-Cladaras, Vassilis I. Zannis, and Dimitris Kardassis. Mechanism of a transcriptional cross talk between transforming growth factor-β–regulated smad3 and smad4 proteins and orphan nuclear receptor hepatocyte nuclear factor-4. Molecular Biology of the Cell, 14(3):1279–1294, March 2003. URL: http://dx.doi.org/10.1091/mbc.e02-07-0375, doi:10.1091/mbc.e02-07-0375. This article has 45 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1091/mbc.e02-07-0375)

[5. (Yingling1997Tumor) Jonathan M. Yingling, Michael B. Datto, Carolyn Wong, Joshua P. Frederick, Nicole T. Liberati, and Xiao-Fan Wang. Tumor suppressor smad4 is a transforming growth factor β-inducible dna binding protein. Molecular and Cellular Biology, 17(12):7019–7028, December 1997. URL: http://dx.doi.org/10.1128/mcb.17.12.7019, doi:10.1128/mcb.17.12.7019. This article has 220 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.17.12.7019)

[6. (Howe1998Mutations) James R. Howe, Stina Roth, John C. Ringold, Robert W. Summers, Heikki J. Järvinen, Pertti Sistonen, Ian P. M. Tomlinson, Richard S. Houlston, Steve Bevan, Frank A. Mitros, Edwin M. Stone, and Lauri A. Aaltonen. Mutations in the smad4/dpc4 gene in juvenile polyposis. Science, 280(5366):1086–1088, May 1998. URL: http://dx.doi.org/10.1126/science.280.5366.1086, doi:10.1126/science.280.5366.1086. This article has 689 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/science.280.5366.1086)

[7. (Kumar2020Deciphering) Rakesh Kumar, Rahul Kumar, Pranay Tanwar, G. K. Rath, Ritesh Kumar, Sunil Kumar, Nihar Dash, Prasenjit Das, and Showket Hussain. Deciphering the impact of missense mutations on structure and dynamics of smad4 protein involved in pathogenesis of gall bladder cancer. Journal of Biomolecular Structure and Dynamics, 39(6):1940–1954, March 2020. URL: http://dx.doi.org/10.1080/07391102.2020.1740789, doi:10.1080/07391102.2020.1740789. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/07391102.2020.1740789)

[8. (Fang2021Prognostic) Tian Fang, Tingting Liang, Yizhuo Wang, Haitao Wu, Shuhan Liu, Linying Xie, Jiaying Liang, Chang Wang, and Yehui Tan. Prognostic role and clinicopathological features of smad4 gene mutation in colorectal cancer: a systematic review and meta-analysis. BMC Gastroenterology, July 2021. URL: http://dx.doi.org/10.1186/s12876-021-01864-9, doi:10.1186/s12876-021-01864-9. This article has 30 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12876-021-01864-9)

[9. (Bardeesy2006Smad4) Nabeel Bardeesy, Kuang-hung Cheng, Justin H. Berger, Gerald C. Chu, Jessica Pahler, Peter Olson, Aram F. Hezel, James Horner, Gregory Y. Lauwers, Douglas Hanahan, and Ronald A. DePinho. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes &amp; Development, 20(22):3130–3146, November 2006. URL: http://dx.doi.org/10.1101/gad.1478706, doi:10.1101/gad.1478706. This article has 527 citations.](https://doi.org/10.1101/gad.1478706)

[10. (Tang2021Hypomorph) Cong Tang, Xiulei Mo, Qiankun Niu, Alafate Wahafu, Xuan Yang, Min Qui, Andrey A. Ivanov, Yuhong Du, and Haian Fu. Hypomorph mutation-directed small-molecule protein-protein interaction inducers to restore mutant smad4-suppressed tgf-β signaling. Cell Chemical Biology, 28(5):636-647.e5, May 2021. URL: http://dx.doi.org/10.1016/j.chembiol.2020.11.010, doi:10.1016/j.chembiol.2020.11.010. This article has 19 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.chembiol.2020.11.010)

[11. (Nolan2017Influential) Bridget E. Nolan, Emily Levenson, and Brian Y. Chen. Influential mutations in the smad4 trimer complex can be detected from disruptions of electrostatic complementarity. Journal of Computational Biology, 24(1):68–78, January 2017. URL: http://dx.doi.org/10.1089/cmb.2016.0162, doi:10.1089/cmb.2016.0162. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1089/cmb.2016.0162)

[12. (Wang2021SMAD4) Yue Wang, Qianqian Xue, Qiang Zheng, Yan Jin, Xuxia Shen, Mu Yang, Xiaoyan Zhou, and Yuan Li. Smad4 mutation correlates with poor prognosis in non-small cell lung cancer. Laboratory Investigation, 101(4):463–476, April 2021. URL: http://dx.doi.org/10.1038/s41374-020-00517-x, doi:10.1038/s41374-020-00517-x. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41374-020-00517-x)

[13. (Zhao2018The) Ming Zhao, Lopa Mishra, and Chu-Xia Deng. The role of tgf-β/smad4 signaling in cancer. International Journal of Biological Sciences, 14(2):111–123, 2018. URL: http://dx.doi.org/10.7150/ijbs.23230, doi:10.7150/ijbs.23230. This article has 388 citations and is from a peer-reviewed journal.](https://doi.org/10.7150/ijbs.23230)

[14. (Ten2002Regulation) Peter Ten Dijke, Marie‐José Goumans, Fumiko Itoh, and Susumu Itoh. Regulation of cell proliferation by smad proteins. Journal of Cellular Physiology, 191(1):1–16, February 2002. URL: http://dx.doi.org/10.1002/jcp.10066, doi:10.1002/jcp.10066. This article has 346 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jcp.10066)

[15. (Wu1997Heteromeric) Rui-Yun Wu, Ying Zhang, Xin-Hua Feng, and Rik Derynck. Heteromeric and homomeric interactions correlate with signaling activity and functional cooperativity of smad3 and smad4/dpc4. Molecular and Cellular Biology, 17(5):2521–2528, May 1997. URL: http://dx.doi.org/10.1128/MCB.17.5.2521, doi:10.1128/mcb.17.5.2521. This article has 286 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/MCB.17.5.2521)

[16. (Wain2014Appreciating) Karen E. Wain, Marissa S. Ellingson, Jamie McDonald, Amanda Gammon, Maegan Roberts, Pavel Pichurin, Ingrid Winship, Douglas L. Riegert-Johnson, Jeffrey N. Weitzel, and Noralane M. Lindor. Appreciating the broad clinical features of smad4 mutation carriers: a multicenter chart review. Genetics in Medicine, 16(8):588–593, August 2014. URL: http://dx.doi.org/10.1038/gim.2014.5, doi:10.1038/gim.2014.5. This article has 56 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/gim.2014.5)